Results 31 to 40 of about 822 (142)
Antibiotics, 2020 Candida auris is an emerging multidrug-resistant fungal pathogen reported worldwide. Infections due to C. auris are usually nosocomial and associated with high rates of fluconazole resistance and mortality.
Mahmoud Ghannoum +11 more
doaj +1 more source
Journal of Fungi, 2021 Ibrexafungerp is a new orally-available 1,3-β-D-glucan synthesis inhibitor in clinical development. Its in vitro activity and that of amphotericin B, voriconazole, and micafungin were evaluated against a collection of 168 clinical isolates of Aspergillus
Olga Rivero-Menendez +3 more
doaj +1 more source
Journal of Fungi, 2023 The epidemiology of invasive fungal infections (IFIs) is currently changing, driven by aggressive immunosuppressive therapy, leading to an expanded spectrum of patients at risk of IFIs.
Roya Vahedi-Shahandashti +3 more
doaj +1 more source
Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis [PDF]
Clinical Infectious Diseases, 2021 Abstract Background Vulvovaginal candidiasis affects approximately 75% of women in their lifetime. Approved treatment options are limited to oral or topical azoles. Ibrexafungerp, a novel, first-in-class oral triterpenoid glucan synthase inhibitor, has demonstrated broad fungicidal Candida activity ...
Nyirjesy, Paul +5 more
openaire +2 more sources
Antifungal resistance, combinations and pipeline: oh my!
Drugs in Context, 2023 Invasive fungal infections are a strong contributor to healthcare costs, morbidity and mortality, especially amongst hospitalized patients. Historically, Candida was responsible for approximately 15% of all nosocomial bloodstream infections.
Kayla R Stover +4 more
doaj +1 more source
1251. Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model [PDF]
Open Forum Infectious Diseases, 2020 Abstract Background Pneumocystis pneumonia (PCP) is an opportunistic fungal infection that affects immunocompromised patients. Ibrexafungerp (IBX) is an oral and intravenous antifungal from a novel class of glucan synthase inhibitors, triterpenoids, and has shown activity against Candida, Aspergillus,
Borroto-Esoda, Katyna +4 more
openaire +1 more source
Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review
Journal of Fungi, 2022 The alarming spread and impact of multidrug-resistant Candida auris infections alongside the limited therapeutic options have prompted the development of new antifungals.
Rogelio de J. Treviño-Rangel +5 more
doaj +1 more source
Hope in the Treatment of Candida Vaginitis: Ibrexafungerp
Türk Mikrobiyoloji Cemiyeti Dergisi, 2021 Candida vaginitis (CV) is a neglected but growing public health problem. It is estimated that three out of four women have had at least one CV attack. The diagnosis and treatment of CV is often inadequate due to the tendency of women to self-diagnose and use over-the-counter drugs when they have vaginal or vulvar complaints, and clinicians plan ...
openaire +1 more source
Ibrexafungerp: a novel oral triterpenoid antifungal, as an emerging therapeutic option in Vulvovaginal Candidiasis (VVC) [PDF]
Infectious Diseases and Tropical Medicine, 2022 OBJECTIVE: Vulvovaginal candidiasis (VVC) is a major concern for women of reproductive age group affecting more than 70% of total population of the mentioned population.
D. Chakraborty, S. Choudhury, S. Lahiry
doaj +1 more source
Ibrexafungerp: A novel oral glucan synthase inhibitor
Medical Mycology, 2019 AbstractIbrexafungerp is a novel glucan synthase inhibitor currently undergoing phase II and phase III clinical trials. This compound has demonstrated in vitro activity against clinically important fungal pathogens including Candida spp. and Aspergillus spp.
M R, Davis +2 more
openaire +2 more sources